NewTrimEra Tirz-Duo
Dual GIP / GLP agonism. Next-generation incretin therapy.
A 39-amino-acid synthetic peptide engineered for simultaneous activation of GIP and GLP receptors, producing superior weight reduction and glycemic effect in head-to-head studies.
How it works
Co-stimulation of GIP and GLP receptors enhances insulin sensitivity, increases adipocyte lipolysis, suppresses appetite centrally, and slows gastric emptying with reduced nausea profile vs. mono-agonists.
What the evidence shows
SURMOUNT-1: up to −22.5% body weight at the 15 mg dose over 72 weeks.
Superior HbA1c reduction vs. semaglutide in SURPASS-2.
Improvements in lipid profile, blood pressure, and hepatic steatosis markers.
First-in-class twincretin approved by the FDA in 2022.
Cited data reflects published clinical trials of the underlying molecule. Individual response varies. Statements have not been evaluated by the FDA.